Contents
pdf Download PDF pdf Download XML
109 Views
33 Downloads
Share this article
Research Article | Volume 10 Issue 2 (None, 2016) | Pages 46 - 48
Erlotinib induced ectropion following papulopustular rash
 ,
 ,
 ,
Under a Creative Commons license
Open Access
PMID : PMC4517803
Received
April 5, 2015
Published
June 30, 2015
Abstract

Background:Erlotinib is a targeted anti-cancer drug which acts through the inhibition of epidermal growth factor receptor (EGFR).Main observations:A 79-year-old developed bilateral ectropion after he received erlotinib treatment for lung adenocarcinoma. The ectropion completely resolved with symptomatic treatment without any modification in erlotinib therapy.Conclusions:EGFR inhibitors are frequently associated with a variety of mucocutaneous adverse events. Ocular toxicity associated with these agents has been reported rarely. We present this case to underline the importance of recognition of newly reported cutaneous and ocular adverse events of targeted therapies.

Keywords
Recommended Articles
Research Article
To Study Dermatoscopic Evaluation Of Cutaneous Lesions Of Leprosy
...
Published: 28/12/2024
Research Article
A Randomized Controlled Trial Comparing the Efficacy and Safety of Oral Colchicine versus Oral Isotretinoin in the Treatment of Lichen Planus Pigmentosus
Published: 22/03/2024
Research Article
Serum Urea and Creatinine Levels in COVID-19 Patients: A Cross-Sectional Study at Sheikh Bhikhari Medical College and Hospital, Hazaribagh
...
Published: 02/09/2025
Original Article
Comparative Evaluation of Intralesional Corticosteroid Injection and Surgical Excision in Hypertrophic Scar Treatment
...
Published: 04/06/2022
© Copyright Spejalisci Dermatolodzy